Cell Lines. (a) The parties acknowledge that PDL has delivered all cell lines to Roche as required under the 1989 Agreements. Roche agrees to deliver back to PDL viable samples of such cell lines as may be requested by PDL.
(b) Ownership of any cell lines developed under Article VI of the 1989 Agreements or delivered to Roche under Milestone #1 of Section 3.1 of the 1989 Agreements, together with their progeny and derivatives, shall remain vested at all times in PDL.
(c) Roche may use the cell lines delivered to it under the 1989 Agreements, or their progeny or derivatives or the plasmids contained therein (the “Cell Line Derivatives”) solely to perform the Roche Commercialization Activities. Furthermore, the Cell Line Derivatives may be used by Roche solely in connection with the genes encoding antibodies developed or provided by PDL.
(d) On the earliest to occur of [*] in the Roche Territory as permitted under this Amended and Restated Worldwide Agreement, Roche shall, on request by PDL, promptly return to PDL all cell lines provided by PDL under the 1989 Agreements and all Cell Line Derivatives.
(e) PDL MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY CELL LINES DELIVERED UNDER THE 1989 AGREEMENTS OR CELL LINE DERIVATIVES USED HEREUNDER, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT. FOR CLARITY, PDL MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND THAT THE USE OF THE CELL LINES DELIVERED TO ROCHE OR THE CELL LINE DERIVATIVES WILL NOT INFRINGE ANY PATENT OR OTHER RIGHTS OF ANY THIRD PARTY.
Cell Lines. Promptly following the execution of this Agreement and during the course of the Collaboration Program Term, and subject to Section 2.2(c), Xxxxx will share with Clovis cell lines in its Control relevant to the Agreed Compound Profile as well as other relevant cell lines developed as part of the Collaboration Program (e.
Cell Lines. Title to the PC3 and LNCaP cell lines shall vest with JBI, and Aduro may not use them for any purpose other than to satisfy its obligations under this Agreement.
Cell Lines. In the event Client expressly requires OXB to use a cell line (“Cell Line”) for which OXB does not have a use right or licence, then OXB shall promptly notify Client thereof and following such notice, if Client requests OXB to obtain such licence, OXB shall seek to obtain such a license and Client shall reimburse OXB’s actual out-of-pocket costs and FTE costs incurred in relation to obtaining a licence to use such Cell Line in the provision of Services; provided, however, OXB shall keep Client fully and timely informed of the process with respect to obtaining such a license. For the avoidance of doubt, OXB shall not be required to use any such Cell Line unless and until OXB has obtained such a licence.
Cell Lines. If OXB, as part of Technology Transfer, makes available to Client any cell lines or other physical materials relating to the Manufacturing process, Client acknowledges and agrees that Client may need to obtain a licence to use such cell lines or physical materials from a Third Party to use such cell lines or other physical materials. Prior to using any such cell lines or physical materials in the performance of this Agreement, OXB shall disclose the identity of such cell lines to Client and obtain Client’s approval with respect to the use thereof.
Cell Lines. The term "20 Cell Lines" shall mean the twenty tumor cell lines listed in Appendix A of this Release Agreement, including all progeny, modified and unmodified derivatives, secretions and antigens thereof.
Cell Lines. In the event Client requests or a Scope of Work or Work Order requires that OXB use a cell line for which OXB does not have a use right or licence (each, a “Third Party Cell Line”), OXB shall request the proposed licence terms from the relevant Third Party, and upon receipt of such licence terms shall provide them to Client for consideration. If Client provides written approval of the licence terms, OXB shall seek in good faith to procure the licence to use such Third Party Cell Line in the provision of Services on such licence terms, and Client shall reimburse the consideration paid by OXB to the Third Party for such licence (in accordance with the licence terms as approved by Client) and OXB’s actual, reasonable and documented costs in relation to obtaining such a licence. For the avoidance of doubt, OXB shall not and shall not be required to use any such Third Party Cell Line in the provision of Services unless and until Client has given its written approval for OXB to obtain, and OXB has obtained, a licence to use such Third Party Cell Line in the provision of Services in accordance with this clause 3.10.
Cell Lines. If OXB, as part of Technology Transfer, makes available to Client (or, if applicable pursuant to clause 13.2, Client’s Affiliate or Third-Party designee) any Third-Party Cell Lines or other physical materials relating to the Process, Client acknowledges and agrees that Client (or such Affiliate or Third-Party designee) may need to obtain a licence to use such cell lines or physical materials from a Third Party to use such cell lines or other physical materials to manufacture the Vector in accordance with the applicable Process after the Technology Transfer; provided that, except with respect to Third-Party Cell Lines that Client requests in writing OXB to use with respect to the Process, OXB shall have identified in Schedule 6 or the applicable Scope of Work or Work Order all such Third-Party Cell Lines and other physical materials.
Cell Lines. D1 cells, a long-term growth factor-dependent immature myeloid dendritic cell line of splenic origin derived from a female C57BL/6 mouse was cultured at 37°C with 5% CO2 in IMDM (Iscove’s Modified Dulbecco’s Medium, Lonza) 63. B3Z, a CD8+ T cell hybridoma specific for the SIINFEKL epitope of OVA 64 was maintained in IMDM (Iscove’s Modified Dulbecco’s Medium, Lonza) sup- plemented with 100 IU/mL penicillin/streptomycin (Gibco™, Bleiswijk, the Neth- erlands), 2 mM glutamine (Gibco, Bleiswijk, the Netherlands), 25 μM 2-mercap- toethanol and 500 μg/mL Hygromycin B (AG Scientific, San Diego, USA).
Cell Lines. Two 1.5 ml vials of the CHOK1SV-GS-KO cell line
